Kathleen Neville
Researcher
Also affiliated: Rutgers, The State University of New Jersey (1996); Children's Oncology Group (2004); Arkansas Children's Hospital (2015–2022); University Health Network (2013); Children's Mercy Hospital (2008–2015); Johnson & Johnson (United States) (2022); Pediatric Oncology Group (2007); University of Kansas (2020); Baylor College of Medicine (2002–2007); University of Arkansas Medical Center (2015–2022); University Medical Center (1994); University Hospital and Clinics (1994); Bellevue Hospital Center (1994); Indiana University Bloomington (2007); Mercy Hospital (2008–2015); UPMC Hillman Cancer Center (2004); National Cancer Institute (2004); Pediatrics and Genetics (2015); Texas Children's Hospital (2002); Children's Cancer Center (2002–2007); Arkansas Department of Agriculture (2016); Mercy Hospital (2013); Indiana University School of Medicine (2006); Indiana University – Purdue University Indianapolis (2004–2006); New York University (1994); University of Missouri–Kansas City (2008–2014)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Kathleen Neville's research focuses on the molecular and genetic underpinnings of childhood diseases, with a particular emphasis on sickle cell anemia and solid tumors. Her work has investigated the efficacy of treatments like hydroxyurea for primary stroke prevention in children with sickle cell anemia, as demonstrated by her involvement in the SPRING trial conducted in Nigeria. Neville has also explored the complex molecular landscape of relapsed and refractory childhood solid tumors, employing genomic and transcriptomic analysis to understand mechanisms of disease progression and immune evasion.
Her research extends to pharmacokinetic studies, such as the analysis of bleomycin sclerotherapy in patients with vascular malformations. With an h-index of 28 and over 4,300 citations across 90 publications, Neville is recognized as a highly cited researcher. She actively collaborates with colleagues at the University of Arkansas for Medical Sciences, including Shelley E. Crary, Joana M. Mack, Gresham T. Richter, and Jeffery H. Moran, and maintains an active laboratory website.
Metrics
- h-index: 29
- Publications: 90
- Citations: 4,342
Selected Publications
-
Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion (2023)
-
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial (2022)
-
Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations (2022)
-
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion (2021)
-
Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial (2020)
-
Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers (2020)
-
Moderate fixed‐dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the <scp>SPIN</scp> trial (2020)
-
Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease (2020)
-
THER-21. TARGETING LIN28 WITH DFMO IN PATIENTS WITH ETMR SUGGESTS CLINICAL BENEFIT (2019)
-
Implementing a standard-of-care clinic for stroke prevention in children with sickle cell disease in Nigeria: a feasible strategy outside a clinical trial setting (2017)
-
Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (2017)
-
Pharmacokinetics of two 6‐mercaptopurine liquid formulations in children with acute lymphoblastic leukemia (2017)
-
The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy (2017)
-
Feasibility Trial for Primary Stroke Prevention in Children with Sickle Cell Anemia in Nigeria (SPIN Trial) (2016)
-
Pharmacokinetics in Children with Sickle Cell Anemia Following Single Dose Versus Chronic Treatment with Hydroxyurea (2016)
Collaboration Network
Top Collaborators
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
- Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
Similar Researchers
Based on overlapping research topics